Kisqali (Ribociclib)
Kisqali (Ribociclib)
Kisqali (Ribociclib) is used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. As a CDK4/6 inhibitor, Kisqali effectively slows down the growth of cancer cells by interfering with their division and proliferation.Why Choose Kisqali (Ribociclib)?
- Effective Combination Therapy: Works effectively in conjunction with an aromatase inhibitor or fulvestrant in premenopausal, perimenopausal, and postmenopausal women.
- Progression-Free Survival: This has been shown to significantly increase progression-free survival compared to endocrine therapy alone.
- Oral Administration: Convenient oral tablet form, facilitating ease of use in outpatient settings.
- Flexible Dosing: Available in multiple dosages, allowing for flexible treatment regimens tailored to patient needs.
How to Use Kisqali (Ribociclib)?
- Dosage and Administration: Kisqali is taken orally, once daily for 21 consecutive days followed by 7 days off to complete a 28-day cycle. It should be taken with or without food at approximately the same time each day.
- Combination Therapy: Must be used in combination with an aromatase inhibitor or fulvestrant as directed by a healthcare provider.
- Monitoring: Regular monitoring of blood counts and liver function tests is required to adjust doses to manage side effects effectively.
Important Safety Information about Kisqali
- Not for Everyone: Kisqali is not suitable for patients with known severe hypersensitivity to ribociclib or any of its components.
- Blood Cell Counts: Patients must have their complete blood count monitored before starting treatment and regularly throughout treatment as Kisqali can result in low white blood cell counts.
- Heart Health: Patients should have heart function tests before and during treatment since Kisqali can cause heart problems.
Fact Table
| Facts | Details |
| Generic Name | Ribociclib |
| Brand Name | Kisqali |
| Drug Class | CDK4/6 inhibitor |
| FDA Approval | Initially approved in March 2017 |
| Indication | Used for the treatment of HR+/HER2- advanced or metastatic breast cancer |
| Administration | Oral tablets |
| Dosage Form | Tablets available in 200 mg, 400 mg, and 600 mg |
| Treatment Regimen | 21 days on, 7 days off to complete a 28-day cycle |
| Combination Therapy | Often used with an aromatase inhibitor or fulvestrant |
| Primary Side Effects | Neutropenia, leukopenia, fatigue, nausea, vomiting, headache, hair loss |
| Monitoring Requirements | Blood counts, liver function, heart function tests |
| Special Considerations | Not suitable for patients with severe hypersensitivity to ribociclib or its components. Requires periodic monitoring of liver function and blood cell counts. |
| Mechanism of Action | Inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in the proliferation of cancer cells |
Common Side Effects
Like all medications, Kisqali (Ribociclib) can cause side effects, although not everybody gets them. Understanding these side effects can help you use this medication safely and effectively.- Fatigue
- Nausea and Vomiting
- Headache
- Hair Loss
How Can You Buy Kisqali (Ribociclib)?
You can order Kisqali (Ribociclib) using these methods on our website:- Order Online
- Order by Phone
- Order by Fax
- Order your refills
